What Is a Good ApoB Level?

Why ApoB Matters More Than LDL Cholesterol

Standard lipid panels report LDL cholesterol as a concentration of cholesterol mass, but what actually drives plaque formation is the number of atherogenic particles penetrating the arterial wall. ApoB gives you that particle count directly. Every LDL, VLDL, IDL, and lipoprotein(a) particle carries exactly one ApoB molecule, so a single ApoB measurement captures total atherogenic burden in a way that LDL-C cannot.

A 2012 meta-analysis of 12 statin trials published in The Lancet (N=38,153) found that on-treatment ApoB was a stronger predictor of major cardiovascular events than on-treatment LDL-C [1]. The discordance between these two markers becomes most clinically relevant in patients with insulin resistance, metabolic syndrome, or elevated triglycerides. In these populations, LDL-C can appear "normal" while ApoB remains high, because each LDL particle is smaller and cholesterol-depleted. A person with an LDL-C of 100 mg/dL might have 900 or 1,400 atherogenic particles depending on their metabolic state. Only ApoB reveals the difference.

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias explicitly recommend ApoB measurement as a secondary treatment target, particularly when triglycerides exceed 200 mg/dL or LDL-C is very low [2]. The Canadian Cardiovascular Society goes further, calling ApoB the "preferred marker of atherogenic particle concentration" [3].

What the Numbers Mean: ApoB Reference Ranges

For adults without established cardiovascular disease and fewer than two traditional risk factors, an ApoB below 90 mg/dL is considered acceptable by most guideline bodies. That number drops sharply as risk rises.

The 2019 ESC/EAS framework stratifies targets by cardiovascular risk category [2]:

• Low risk: ApoB <100 mg/dL
• Moderate risk: ApoB <80 mg/dL
• High risk (e.g., diabetes without organ damage, moderate CKD): ApoB <65 mg/dL
• Very high risk (e.g., prior MI, stroke, or diabetes with organ damage): ApoB <55 mg/dL

The American College of Cardiology and American Heart Association 2018 cholesterol guidelines do not set a formal ApoB target but acknowledge ApoB as a "risk-enhancing factor" that can guide statin initiation in borderline-risk patients [4]. A measured ApoB at or above 130 mg/dL is considered elevated regardless of risk category.

Population studies put the median ApoB for U.S. adults near 95 mg/dL, meaning roughly half the adult population exceeds the low-risk threshold. This is not surprising given that cardiovascular disease remains the leading cause of death in the United States, accounting for approximately 928,741 deaths in 2020 according to CDC data [5].

How ApoB and LDL-C Become Discordant

Discordance is the clinical scenario where ApoB and LDL-C send conflicting signals. It happens frequently. A 2011 analysis of the Framingham Offspring Study (N=3,066) found that 29% of participants had discordant ApoB and LDL-C values [6]. Among those with discordance, cardiovascular event rates tracked with ApoB, not LDL-C.

Three common causes of discordance:

Insulin resistance and metabolic syndrome. Hepatic overproduction of VLDL leads to triglyceride-rich, cholesterol-poor LDL particles. Particle count is high, but cholesterol per particle is low, so LDL-C underestimates true risk.

Familial hypercholesterolemia. Large, cholesterol-rich LDL particles inflate LDL-C relative to particle number. Here, LDL-C may overestimate risk compared to ApoB, though both will be elevated.

Low LDL-C on therapy. Patients on moderate-intensity statins may achieve an LDL-C of 70 mg/dL while ApoB remains above 80 mg/dL, suggesting residual particle-driven risk. The INTERHEART study (N=27,098 across 52 countries) showed that the ApoB/ApoA1 ratio was the strongest predictor of myocardial infarction among all lipid measures tested [7].

When your LDL-C and ApoB disagree, trust ApoB for risk stratification. This principle now appears in Canadian, European, and several national Asian guidelines.

Should Everyone Over 40 Take a Statin?

Not everyone, but the threshold is lower than many patients expect. The 2018 ACC/AHA guidelines recommend statin therapy for four specific groups: patients with clinical ASCVD, those with LDL-C at or above 190 mg/dL, adults aged 40-75 with diabetes, and adults aged 40-75 with a 10-year ASCVD risk at or above 7.5% [4]. An elevated ApoB can tip the decision toward treatment in borderline-risk patients (5-7.5% 10-year risk).

The CTT (Cholesterol Treatment Trialists') Collaboration meta-analysis of 26 statin trials (N=170,000) demonstrated a 21% relative reduction in major vascular events per 1.0 mmol/L reduction in LDL-C, with consistent benefit across age groups up to 75 [8]. High-intensity regimens (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) typically lower ApoB by 40-55%.

For patients who cannot tolerate statins, alternatives include ezetimibe (which reduces ApoB by an additional 10-15% when added to a statin) and PCSK9 inhibitors such as evolocumab and alirocumab, which can cut ApoB by 45-55% on top of statin therapy. The FOURIER trial (N=27,564) showed that evolocumab added to statin therapy reduced ApoB by 52% and major cardiovascular events by 15% over a median of 2.2 years [9].

Bempedoic acid (Nexletol) offers another option for statin-intolerant patients. The CLEAR Outcomes trial (N=13,970) showed that bempedoic acid reduced LDL-C by 21% and major adverse cardiovascular events by 13% in statin-intolerant patients [10].

Are CoQ10 Supplements Needed on Statins?

Statins inhibit HMG-CoA reductase, the same enzyme pathway that produces coenzyme Q10 (CoQ10). Blood levels of CoQ10 drop by 16-54% on statin therapy, which has led to widespread speculation that CoQ10 depletion causes statin-associated muscle symptoms (SAMS).

The evidence is mixed. A 2018 Cochrane systematic review of 12 randomized controlled trials (N=575) found no convincing evidence that CoQ10 supplementation reduces statin-associated muscle pain [11]. Most trials were small, short, and heterogeneous in dosing.

Some patients do report subjective improvement. A 2015 double-blind RCT (N=50) published in Medical Science Monitor found that CoQ10 100 mg twice daily reduced muscle pain severity by 33% compared to placebo in patients with confirmed statin myalgia [12]. The clinical significance of this effect remains debated.

Current ACC/AHA guidelines do not recommend routine CoQ10 supplementation for patients on statins [4]. For patients experiencing muscle symptoms, the guidelines suggest trying a different statin, lowering the dose, or switching to every-other-day dosing of rosuvastatin before adding supplements.

If a patient chooses to try CoQ10, typical study doses range from 100 to 200 mg daily in the ubiquinol form, which has better bioavailability than ubiquinone. CoQ10 has no significant drug interactions with statins.

Best Blood Pressure Medications for Athletes

Athletes present a unique challenge in antihypertensive selection because many commonly prescribed agents affect heart rate, exercise capacity, or are banned in competitive sports.

ACE inhibitors (e.g., lisinopril, ramipril) and ARBs (e.g., losartan, telmisartan) are generally considered first-line for hypertensive athletes. They do not impair exercise performance, are not on the World Anti-Doping Agency (WADA) prohibited list, and provide renal protection. The 2018 ESC recommendations on sports cardiology specifically support ACE inhibitors and ARBs as preferred agents for athletes with hypertension [13].

Beta-blockers should be avoided in most athletic populations. They reduce maximal heart rate, decrease cardiac output during exertion, and limit peak exercise capacity by 5-15%. They are also prohibited by WADA in several sports including archery, shooting, and golf [14]. The exception is athletes with specific arrhythmias or post-MI patients where the benefit clearly outweighs the performance cost.

Calcium channel blockers (amlodipine type) are a reasonable second-line choice. Amlodipine does not affect heart rate or exercise tolerance. Non-dihydropyridine agents (diltiazem, verapamil) slow heart rate and are less suitable.

Thiazide diuretics are banned by WADA as masking agents and also cause electrolyte shifts that increase cramping and dehydration risk during prolonged exercise [14]. They should be avoided in competitive athletes.

The target for office blood pressure in athletes matches general population goals: below 130/80 mmHg per the 2017 ACC/AHA hypertension guidelines [15]. White-coat hypertension is common in athletes, so ambulatory blood pressure monitoring (ABPM) should be used before starting therapy.

Should I Take Aspirin for Prevention?

The answer has shifted dramatically in recent years. Low-dose aspirin (75-100 mg daily) was once recommended broadly for primary cardiovascular prevention, but three major trials published in 2018 changed the calculus.

ASPREE (N=19,114 adults aged 70 and older) found no cardiovascular benefit from aspirin 100 mg daily and an increased rate of major hemorrhage (3.8% vs. 2.8% placebo over 4.7 years) [16]. ARRIVE (N=12,546 moderate-risk adults) showed no reduction in cardiovascular events with aspirin [17]. ASCEND (N=15,480 adults with diabetes) found that aspirin reduced vascular events by 12% but increased major bleeding events by 29%, resulting in a net effect close to zero [18].

Based on these trials, the U.S. Preventive Services Task Force (USPSTF) updated its 2022 recommendation: adults aged 40-59 with a 10-year ASCVD risk of 10% or greater may consider aspirin initiation only if they are not at increased bleeding risk, and the decision should be individualized [19]. For adults 60 and older, the USPSTF recommends against initiating aspirin for primary prevention.

Aspirin remains clearly indicated for secondary prevention. Anyone who has had a heart attack, ischemic stroke, or established peripheral artery disease should continue aspirin 75-100 mg daily unless contraindicated.

"The era of widespread aspirin use for primary prevention is over," stated Dr. Roger Blumenthal, co-chair of the 2019 ACC/AHA Primary Prevention guidelines [4]. "We now reserve aspirin for patients who have already had a cardiovascular event or who are at very high risk with low bleeding risk."

How to Lower Your ApoB

Lowering ApoB requires targeting the production and clearance of atherogenic lipoproteins. The most effective interventions, ranked by expected ApoB reduction:

High-intensity statin therapy: 40-55% ApoB reduction. This remains the cornerstone. Rosuvastatin 20-40 mg or atorvastatin 40-80 mg achieves the greatest effect [8].

PCSK9 inhibitors (added to statin): Additional 45-55% ApoB reduction. Evolocumab (140 mg every 2 weeks) or alirocumab (75-150 mg every 2 weeks) are FDA-approved options [9].

Ezetimibe (added to statin): Additional 10-15% ApoB reduction by blocking intestinal cholesterol absorption [4].

Inclisiran: A twice-yearly injectable siRNA that lowers ApoB by approximately 35% as monotherapy. The ORION-11 trial (N=1,617) demonstrated sustained LDL-C reduction of 54% at 510 days [20].

Dietary modification: A portfolio dietary pattern (plant sterols, viscous fiber, soy protein, almonds) reduced ApoB by 17% in a 2011 randomized trial published in CMAJ (N=351) [21]. Mediterranean dietary patterns show ApoB reductions of 5-10%.

Weight loss: Each 10 kg of weight loss reduces ApoB by approximately 5-10 mg/dL, with greater reductions in patients with metabolic syndrome [2].

For patients on GLP-1 receptor agonists like semaglutide or tirzepatide for weight management, there is an additional indirect ApoB benefit through improved insulin sensitivity and visceral fat reduction. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo, and post-hoc analyses revealed concurrent improvements in atherogenic lipoproteins [22].

When to Recheck ApoB After Starting Treatment

After initiating or adjusting lipid-lowering therapy, recheck ApoB at 4-12 weeks. This window allows the medication to reach steady state and hepatic LDL receptor upregulation to stabilize.

If the initial ApoB was 120 mg/dL and the target is 65 mg/dL, a high-intensity statin alone (producing roughly 50% reduction) would bring ApoB to approximately 60 mg/dL, which meets the target. If after 8 weeks ApoB remains above goal, adding ezetimibe is the standard next step before considering PCSK9 inhibition.

Annual monitoring is reasonable once ApoB is at target. No fasting is required for ApoB measurement, which makes it more convenient than a full fasting lipid panel. "ApoB should be measured in all patients being evaluated for metabolic risk and in all patients on lipid-lowering therapy," wrote Dr. Allan Sniderman in a 2019 position paper in The Lancet [23]. Lab cost is typically $20-40 with insurance, comparable to a standard lipid panel.

Patients taking statins should also monitor liver enzymes (ALT) at baseline and as clinically indicated, and report unexplained muscle pain promptly. The absolute risk of rhabdomyolysis on statin therapy is approximately 1 per 10,000 patient-years [8].